September 2026 Research Update

This month, the strongest message from real-world studies is that PNH remains a high-burden disease in settings where complement inhibitors are not widely used, and that treatment patterns vary sharply by region. Large datasets described ongoing hemolysis (red blood cell breakdown) and symptoms like fatigue, along with relatively low use of eculizumab in routine care. In smaller cohorts with limited access to C5 inhibitors, delayed diagnosis and serious complications were common, and survival outcomes were poorer. [1] [2]

In a large Chinese registry of 716 people, classic PNH and bone marrow failure-associated PNH were both common, and many had lab signs of active hemolysis along with symptoms such as fatigue and dark urine. Even with this disease activity, eculizumab use was reported in about 28.5% of patients at baseline or follow-up, alongside substantial use of supportive approaches like steroids. This helps put numbers around the gap that can exist between disease burden and access to targeted treatment in real-world care. [1]

Two Indian center reports described PNH care largely without complement inhibitors and showed a different picture dominated by complications of low blood counts and limited treatment options. In South India (45 patients), time to diagnosis averaged about 1.88 years, pancytopenia was frequent, and 5-year overall survival was 57.6%, with infections and bleeding leading causes of death. In North India (211 patients with large clones), thrombosis was reported in 6.6% and some patients achieved partial or complete responses with the therapies available, but deaths still occurred in about 19% of those with known survivorship status. [2] [3]

One part of the North Indian cohort focused on primary prevention of blood clots in classical PNH using low-dose apixaban in a subset. Among 20 patients who received this approach, the report noted no thrombosis and no bleeding events during follow-up as described. Because this was not a randomized comparison and details about who was selected for prophylaxis are limited in the summary, it should be read as an observation that needs confirmation rather than a proven effect. [3]

For patients and caregivers, these studies mainly add clarity about what living with PNH looks like in everyday care across different health systems, rather than pointing to a new standard treatment. They show that fatigue, dark urine, and lab signs of hemolysis can remain prominent, and that delays in diagnosis and limited access to complement inhibitors may be linked with more complications in some settings. What remains uncertain is how much of the outcome differences are driven by access to specific drugs versus differences in patient mix and disease severity at the time of diagnosis. This matters now as context for understanding why experiences with PNH can look very different across countries, and it may guide future efforts to improve access and earlier recognition. [1] [2] [3]

This month added detail on what patients may still feel and what clinicians may monitor during PNH, while also surfacing a safety signal in a separate heart-attack population. Fatigue remained common even among people already treated with eculizumab, suggesting that symptom burden does not always disappear with complement blockade. An Italian expert consensus laid out a structured approach to diagnosis and follow-up testing, reflecting a push toward more consistent monitoring. Separately, a large health-record analysis in people with STEMI reported higher risks of several complications in those with prior C5 inhibitor exposure, though the underlying diseases were mixed and not limited to PNH. [4] [5] [6]

In a Turkish multicenter study of 104 adults with PNH receiving eculizumab, about 37.5% met the study definition of severe fatigue on a standardized questionnaire. Severe fatigue was reported more often in women and in those with other medical conditions, and it was linked with lower hemoglobin at diagnosis. This helps emphasize that fatigue in PNH can be influenced by more than one factor, and that people may still report major day-to-day impact even while on a complement inhibitor. [4]

The Italian consensus statement reinforced that diagnosis and follow-up often depend on sensitive flow cytometry testing to measure the PNH clone, plus regular checks of blood counts and hemolysis markers. It also highlighted baseline evaluation for clot risk and organ problems, and it included education topics such as infection risk and breakthrough hemolysis during treatment. Because this is expert guidance rather than a study testing outcomes, it mainly reflects how specialists aim to standardize care processes rather than proving that a particular monitoring schedule improves results. [5]

A global database study looked at adults with STEMI (a severe type of heart attack) and compared those who had previously received eculizumab or ravulizumab with matched patients who had not. At 365 days, the group with prior C5 inhibitor exposure had higher reported rates of death, stroke or TIA, blood clotting disorders, major cardiovascular events, and acute kidney injury, while arrhythmia was lower. Because people took C5 inhibitors for several different diseases (including PNH), and because this kind of study cannot fully separate drug effects from underlying illness severity, the results are best understood as a cautionary signal that needs deeper study. [6]

For patients, these studies mainly help set expectations and explain why follow-up may involve more than checking whether hemolysis is controlled. The fatigue study suggests that a sizable number of people on eculizumab still report severe fatigue, and that anemia history and other health conditions may relate to how tired someone feels. The consensus document signals that many centers aim for ongoing, structured monitoring (including repeat clone testing and watching for breakthrough hemolysis and infections), but it does not prove that one schedule is best. The STEMI database study may matter later if confirmed, because it raises questions about outcomes after a heart attack in people previously treated with C5 inhibitors, but it is not specific to PNH and does not show cause and effect. [4] [5] [6]

This month included early-stage reports that do not change typical care but expand understanding of edge cases and biology. Two single-patient reports highlighted that PNH can intersect with complex procedures or with bone marrow failure conditions in ways that change risks and monitoring needs. A small laboratory study identified a specific platelet protein affected by the GPI-anchor problem in PNH, offering a more detailed map of what is missing on PNH platelets. These findings are most useful for explaining mechanisms and rare situations rather than predicting what will happen for most patients. [7] [8] [9]

One case report described a person with PNH receiving pegcetacoplan (a complement-targeting treatment) who developed severe breakthrough hemolysis after therapeutic plasma exchange done for transplant preparation. The authors discussed possible triggers including the procedure potentially removing pegcetacoplan and transfusion-related factors. The key point is that certain intensive medical procedures may create conditions where hemolysis can break through even during treatment, although this is a single case and may not apply broadly. [7]

Another case report involved aplastic anemia with PNH overlap, where a low-level chromosome 17p deletion was detected but there was no other evidence of a myeloid cancer on additional testing. The patient became transfusion-independent after immunosuppressive and supportive therapies and remained stable for 27 months as reported. This case shows that some genetic findings can appear in AA-PNH without clear progression to a new blood cancer, but longer observation is needed to know how often this is reassuring. [8]

A case series focused on abdominal pain as a first sign of rare blood disorders, including one person later diagnosed with PNH. It mainly serves as a reminder that PNH can sometimes first show up in non-obvious ways, such as abdominal pain, but the report does not quantify how often this happens. Because it includes only one PNH patient among four different diseases, it should be read as illustrative rather than representative. [10]

In laboratory work using platelets from a small number of PNH patients and healthy donors, researchers identified fibrocystin L (PKHD1L1) as a large GPI-anchored receptor that is missing in PNH platelets. The protein appeared on the platelet surface after activation and seemed to be stored in granule-like areas inside the platelet. This adds detail to how the PNH defect affects platelets, but the study did not establish what the protein does in the body or how it relates to symptoms like clotting. [9]

For patients and caregivers, this section mainly helps explain exceptions and early research rather than offering new proven options. The pegcetacoplan case highlights that breakthrough hemolysis can occur during unusual high-intensity situations like plasma exchange before transplant, but it is not evidence that this will happen for most people. The AA-PNH overlap case suggests that some chromosome changes can be found without clear evolution to another blood cancer, yet it remains uncertain how this applies to others because it is a single report. The platelet biology finding may matter later by improving scientific understanding of clotting and platelet function in PNH, but it is not a clinical test and does not predict outcomes on its own. [7] [8] [10] [9]